Skip to content

Clinical Research of Laparoscopic Radical Cystectomy with Intracorporeal Orthotopic Ileal Neobladder

Clinical Research of Laparoscopic Radical Cystectomy with Intracorporeal Orthotopic Ileal Neobladder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006007
Enrollment
Unknown
Registered
2015-01-30
Start date
2015-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Carcinoma

Interventions

Control:open radical cystectomy with extracorporeal orthotopic ileal neobladder
Experimental:laparoscopic radical cystectomy with extracorporeal orthotopic ileal neobladder

Sponsors

Beijing Chao-Yang Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Muscle-invasive bladder cancer (T2-T4a, N0-x, M0); Multiple recurrent non-muscle invasive bladder cancer; G3 non-muscle invasive bladder cancer; multiple carcinoma in situ; extensive papillary disease can not be controlled by conservasive treatment; recurrent or unresponse after bladder-preserving treatment; Non-transitional cell carcinoma in bladder; 2. Normal function of urethral sphincter; 3. Zubrod-ECOG-WHO (ZPS) Grade:0-2; Karnofsky Perfromance Status (KPS) >=60; 4. Patients provided voluntary informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patient with distant metastasis disease; 2. Tumor in urethral (Tumor locate below bladder neck in male, and trigone of bladder in female); 3. Co-exist disease which may affect intraabdominal pressure (esophageal hiatal hernia, abdominal hernia, abnormal abdominal or pelvic straining; 4. Stricture of anterior urethra; 5. Co-exist intestinal disease; 6. Previous resection of small intestine; 7. Severe heart insufficiency, decompensated pulmonary, liver, renal functons, or other severe systemic disease; 8. Stress incontinence in femal or previous bladder nek suspension; 9. Other situation which was recognized should be excluded by the researcher.

Design outcomes

Primary

MeasureTime frame
Intraoperative and postoperative complications;Oncological outcomes;Operation time;

Secondary

MeasureTime frame
Estimated blood loss;Hospital stay;Time to liquid diet;Time to regular diet;

Countries

China

Contacts

Public ContactNianzeng Xing
nianzeng2006@vip.sina.com+86 18601238866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026